Overview

Study of Denosumab in Subjects With Giant Cell Tumor of Bone

Status:
Completed
Trial end date:
2018-05-17
Target enrollment:
Participant gender:
Summary
To determine how safe denosumab is in treating subjects with giant cell tumor of bone (GCTB)
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Denosumab
Immunoglobulin G
Immunoglobulins